Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Vaccine market boosters

Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Patel, H. & Makarova, A. Emerging Vaccines (Decision Resources Waltham, Massachusetts, December 2008).

    Google Scholar 

  2. Giuliani, M.M. et al. Proc. Nat. Acad. Sci. USA 103, 10834–10839 (2006).

    Article  CAS  Google Scholar 

  3. Pass, R.F. et al. NEJM 360, 1191–1199 (2009).

    Article  CAS  Google Scholar 

  4. Reap, E.A. et al. Vaccine 25, 7441–7449 (2007).

    Article  CAS  Google Scholar 

  5. Wloch, M.K. et al. J. Infect. Dis. 15, 1634–1642 (2008).

    Article  Google Scholar 

  6. Kuklin, N.A. et al. Infect. Immun. 74, 2215–2223 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Sheridan, C. Vaccine market boosters. Nat Biotechnol 27, 499–501 (2009).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing